Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial

Medicine & Life Sciences

• Staphylococcal Pneumonia 100%
• Ventilator-Associated Pneumonia 90%
• Placebos 48%
• Safety 41%
• Pneumonia 19%
• Incidence 17%
• Random Allocation 11%
• Artificial Respiration 11%
• Respiratory System 11%
• Anniversaries and Special Events 10%
• Intensive Care Units 9%
• Therapeutics 9%
• Glasgow Coma Scale 9%
• APACHE 9%
• Anti-Bacterial Agents 7%
• Intention 7%
• Clinical Trials Data Monitoring Committees 6%
• Chronic Disease 5%
• Monoclonal Antibodies 5%
• Infections 5%
• Organ Dysfunction Scores 5%
• Hungary 4%
• Portugal 4%
• Czech Republic 4%
• Greece 4%
• Polymerase Chain Reaction 4%
• Belgium 4%
• Switzerland 4%
• Negative Results 4%
• Risk Reduction Behavior 4%
• Intravenous Infusions 3%
• Spain 3%
• France 3%
• Lung Diseases 3%
• Germany 3%
• Staphylococcus aureus 3%
• Population 3%
• Pharmacokinetics 2%
• Research Personnel 2%
• Aptitude 2%
• Databases 2%
• Lung 2%